Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH

Corporate Breaking News

Home : Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH

Dec 03 2018	Nordic Nanovector: Single Administration Betalutin® is Effective and Well-tolerated in R/R iNHL Patients: 6 Month Follow-up Data Presented at ASH
OSLO, Dec. 3, 2018 /PRNewswire/ -- Overall response rate (ORR) of 61% and complete response (CR) rate of 28% in 74 patients with indolent non-Hodgkin's lymphoma (iNHL) Highly active in follicular lymphoma (FL) patients with ≥2 prior therapies (n=37) (ORR 70% CR 32%), and...


Source:https://www.prnewswire.com:443/news-releases/nordic-nanovector-single-administration-betalutin-r-is-effective-and-well-tolerated-in-r-r-inhl-patients-6-month-follow-up-data-presented-at-ash-841004804.html

Related News
» SAFR, Advanced Facial Recognition Technology from RealNetworks, Enters the China Market Through Homtar Corporation » Anders Lönner, Chairman of the Board Karo Pharma AB, has Suddenly Passed Away